Citi Initiates Coverage on Bristol-Myers Squibb (BMY) with a Neutral
More News related to BMY
- Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner
- Notable Mergers and Acquisitions of the Day 10/06: IMCL/LLY, VSH/IRF, EBAY
- ImClone (IMCL) Enters Merger Agreement With Eli Lilly (LLY) For $70/Share
- Bristol-Myers Squibb Appoints Christopher Perley as Devens General Manager
- ImClone's (IMCL) Carl Icahn Issues Statement On Takeover Bid
More News related to New Coverage
- Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic
- GTC Biotherapeutics (GTCB) Announces FDA Accepts ATryn(R) BLA Filing
- Genentech and OSI Phama Said Avastin/Tarceva Combo Fails As Second-Line Treatment For Lung Cancer
Citi initiates coverage on Bristol-Myers Squibb (NYSE: BMY) with a Neutral. Price target $23.
Citi analyst says, "We project above average 3-year (2008-'11) incremental pharma sales of $4B supported by robust growth from inline brands & improving new product performance. BMY's pipeline score is above its peer group average, with 51% of its score in late stage assets...BMY's superior operational growth outlook, attractive pipeline, ~5.5% dividend yield & prospects for M&A as its "patent cliff" approaches should limit downside risk from current levels."
Bristol-Myers Squibb Company (Bristol-Myers Squibb or BMS), incorporated in August 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare-related products.
Related Categories
New CoverageStocks Mentioned
+0.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
